Pygeum for Health & Longevity - Quick Reference Sheet

Pygeum for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Pygeum is a botanical supplement from African cherry bark, administered orally by aging men to support urinary comfort, bladder emptying, and sleep. High-level, conflicted evidence shows modest improvements in urinary symptoms, nighttime urination, urinary flow, and residual bladder volume in mild-to-moderate prostate enlargement. Evidence for prostate inflammation and hair loss is low, other uses are speculative, mild adverse events match placebo, and supplement quality varies. (Full Review)

Protocol

Standard pharmaceutical extract dose
100 mg/day oral extract
Lipophilic Prunus africana bark extract standardized to 14% total sterols (2.5% β-sitosterol) and 0.5% n-docosanol
Best time of day
Once daily with dinner or split twice daily
100 mg orally with dinner, or 50 mg with breakfast and 50 mg with dinner for absorption and nocturnal comfort
Dose range and integrative combinations
75–200 mg/day monotherapy
Or 50–100 mg/day paired with 600–1,200 mg/day Urtica dioica root extract; urological dosing applies to adult men only
Time to effect
Peak IPSS reductions and urinary flow gains
6–12 months
Peak IPSS reductions (-46%) and urinary flow improvements in benign prostatic hyperplasia
Initial nocturia and urinary urgency
4–8 weeks
Initial symptom relief; 6–8 weeks of continuous daily dosing builds anti-inflammatory and urodynamic effects
Hair density in androgenetic alopecia and telogen effluvium
3–6 months
Gains at 3 months (+5.5 hairs/cm²) and 6 months (+10.8 hairs/cm²) with multi-ingredient oral capsule

Benefits

Contraindications
  • Individuals with known hypersensitivity to Prunus africana or Rosaceae family plants
  • Children and adolescents (< 18 years of age)
  • Pregnant or lactating women
  • Men with acute urinary retention, gross hematuria (visible blood in urine), fever, or suspected prostate cancer
Key Interactions
  • 5α-reductase inhibitors (finasteride, dutasteride) (theoretical)
  • Androgen receptor antagonists and hormone therapies (bicalutamide, enzalutamide, exogenous testosterone) (theoretical)
  • Alpha-1-adrenergic blockers (tamsulosin, alfuzosin, doxazosin) (theoretical)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin) (theoretical)
  • Prostate botanical supplements (saw palmetto/Serenoa repens, stinging nettle/Urtica dioica, β-sitosterol)
  • Fat-absorption inhibitors and bile acid sequestrants (orlistat, cholestyramine, colesevelam) (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild gastrointestinal discomfort; dizziness, headache, visual disturbances, and cutaneous hypersensitivity
  • Speculative: Hepatic, renal, and myocardial biomarker elevations

Monitoring

Marker Target Why
International Prostate Symptom Score (IPSS) ≤ 7 points (mild symptom band per Chatelain et al., 1999) Efficacy marker expected to decrease with treatment.
Peak Urinary Flow Rate (Qmax) No established target; track increase from individual baseline (≥ 1.6–2.5 mL/s gain in trials) Efficacy marker expected to increase with treatment.
Post-Void Residual (PVR) Urine Volume No established target; track reduction from individual baseline (~13 mL or 24% drop in trials) Efficacy marker expected to decrease with treatment.
Serum Prostate-Specific Antigen (PSA) ≤ 1.0 ng/mL (Life Extension optimal target) Safety check to exclude undetected prostate cancer.
Serum Alanine Aminotransferase (ALT) & Creatinine ALT: 7–56 U/L; Creatinine: 0.7–1.3 mg/dL (standard reference range) Safety check to rule out hepatic or renal stress.

Cadence: Baseline testing (IPSS, 3-day nocturnal voiding diary, Qmax, PVR volume, and fasting morning serum PSA, ALT, and creatinine), followed by reassessment at 8 weeks, 6 months, and every 6–12 months thereafter during continuous use (repeating ALT and creatinine for high-dose regimens).

Qualitative Assessment

  • Nocturnal sleep continuity: Frequency of nightly awakenings for urination and ease of returning to sleep.
  • Daytime voiding comfort: Changes in urinary hesitancy, stream force, post-void dribbling, and bladder emptying.
  • Gastrointestinal tolerance: Occurrence of post-dose nausea, upper abdominal discomfort, constipation, or loose stools.